Recent commentary from Baron Capital and a maintained Buy rating from Citigroup have pushed Waystar Holding (WAY) back into focus, as Q1 2026 results highlighted its AI-driven revenue cycle management platform and financial performance.

Despite a 5.58% 1 day share price return bringing the stock to $21.01, the 30 day share price return of 8.09% and year to date share price return of 33.03% point to fading momentum. At the same time, the 1 year total shareholder return of 48.11% underscores how sentiment has cooled even as fresh guidance, Q1 results and renewed institutional interest keep the story in focus.

If you are comparing Waystar with other healthcare technology opportunities, it could be worth scanning a wider field of AI driven healthcare businesses using the 35 healthcare AI stocks

With Waystar now trading at $21.01, sitting on a 33.03% year to date share price decline yet carrying a 65% discount to the average analyst price target, is this weakness a potential entry point or is the market already discounting its future growth?

Most Popular Narrative: 41.6% Undervalued

At a last close of $21.01 versus a narrative fair value of $36.00, the most widely followed view sees a sizeable valuation gap built on specific growth and margin assumptions.

The acquisition of Iodine Software, a leading provider of AI-powered clinical intelligence, will expand Waystar's total addressable market by over 15%, accelerate its product roadmap, and immediately boost gross margins and adjusted EBITDA margins, setting up compounding, long-term revenue and earnings growth.

Want to see what kind of revenue trajectory and margin lift would have to play out to support that value gap? The narrative leans on steady top line expansion, rising profitability and a premium earnings multiple that edges above the sector. The full set of assumptions shows how those pieces are expected to fit together over time.

Result: Fair Value of $36.00 (UNDERVALUED)

However, investors still need to weigh higher leverage from the US$1.25b Iodine deal, as well as the risk that larger provider groups push for tougher pricing over time.

Next Steps

Given that the narrative points to potential upside but also flags real risks, it makes sense to move quickly and pressure test the thesis against the underlying data, starting with the 4 key rewards.

Ready to hunt for more stock ideas?

If Waystar has sharpened your thinking, keep that momentum going by lining up a few more potential opportunities before the next move slips past you.

• Target reliable income by scanning companies with sturdy payouts using the 12 dividend fortresses.
• Spot potential value opportunities quickly by running a focused search through the 51 high quality undervalued stocks.
• Prioritise resilience by filtering for businesses highlighted in the 71 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.